Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
20 a » 20 _ (Expand Search), 20 μ (Expand Search), 20 c (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
20 a » 20 _ (Expand Search), 20 μ (Expand Search), 20 c (Expand Search)
-
701
-
702
-
703
-
704
Overexpression of human PGRN mRNA prevents the decrease in axon outgrowth produced by knockdown of zebrafish PGRN.
Published 2013“…<p>A) The decreased axonal length produced by knockdown of <i>grna</i> with a 5′UTR MO was rescued by co-expression of PGRN mRNA. * significantly different from grna CO MO, p<0.02; ̂ significantly different from <i>grna</i> MO + GFP, p<0.0001. …”
-
705
-
706
-
707
-
708
-
709
-
710
-
711
-
712
-
713
The NK1-receptor antagonist ezlopitant significantly and selectively decreases voluntary intake of both sucrose and ethanol.
Published 2013“…<p>Ezlopitant decreased consumption of 5% sucrose (<b>A</b>), whereas only the highest dose of ezlopitant (10 mg/kg) decreased consumption of 20% ethanol (<b>B</b>). …”
-
714
-
715
-
716
The NK1-receptor antagonist ezlopitant significantly decreases voluntary intake of non-caloric saccharin solution.
Published 2013“…<p>Ezlopitant (5 and 10 mg/kg) significantly decreased consumption of the non-caloric 0.2% saccharin solution compared to vehicle. …”
-
717
-
718
-
719
-
720